二重抗体医薬品の世界市場2022

◆英語タイトル:Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022
◆発行会社/調査会社:RNCOS
◆商品コード:RNCS704003
◆発行日:2017年4月12日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Multi UserUSD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[二重抗体医薬品の世界市場2022]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

The double barreled or bi-specific antibodies concept is progressively gaining traction in the biopharmaceutical industry owing to several therapeutic advantages, as well as their potential to address challenges being faced with the mAb based therapies. Bi-specific antibodies are artificial antibodies developed by joining together two monoclonal antibodies or their parts that target different epitopes. The resulting bi-specific antibody has binding affinities for two or three different epitopes concomitantly.
According to the RNCOS report entitled “Global Double Barreled Antibodies Drug Sales (BLINCYTO & Removab), Pipeline Analysis (By Phase, Technology, and Indication), & Global Market Forecasts 2022”, the double barreled antibodies market is anticipated to reach US$ 604.9 Million by 2022. In this report, there is in-depth market analysis of BLINCYTO and Removab. The double barreled antibodies market is still in its infancy. With the European Medicines Agency approval of Removab in 2009, a great deal of interest has been generated in the bi-specific antibody market. The bi-specific antibodies pipeline is rich and diverse, and has drugs being developed for both oncological and non-oncological indications. These drugs are based on various technological platforms developed by Roche, Amgen, AbbVie, Ablynx, Affimed, and MacroGenics amongst others. The antibody platforms are based on the concepts of chemical cross-linking, hybridomas, as well as recombinant techniques.

During the course of our research, we found bi-specific antibodies currently in different stages of clinical development. Most of these are industry sponsored, and around 2-3 of the bi-specific antibody drugs amongst them are expected to be launched by the end of this decade. In addition to the clinical pipeline, over 30 molecules have been identified which are currently in preclinical/discovery phase. Technological advancements, particularly in the bi-specific antibodies purification will ensure the development of products with improved safety, potency, and efficacy profile. As more products move from pipeline to the market, an increase in the investment in this bi-specific antibodies development is expected from various quarters in coming years. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry’s growth.

In the end, the report enlists some of the key players in the double barreled antibodies market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

*** レポート目次(コンテンツ)***

1. Analyst View
2. Research Methodology
3. Double Barreled Antibodies – An Introduction
4. Double Barreled Antibodies Market Outlook to 2022
4.1 BLINCYTO
4.1.1 Market Potential
4.1.2 Actual Market Size
4.2 Removab
4.2.1 Market Potential
4.2.2 Actual Market Size
5. Double Barreled Antibodies Pipeline Analysis
5.1 By Clinical Phase
5.2 By Indication
5.3 By Technology
6. Market Dynamics
6.1 Drivers
6.1.1 Rising Global Cancer Epidemics
6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs
6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
6.2 Challenges
6.2.1 Production Hurdles in Double Barreled Antibodies Development
6.2.2 Regulatory Challenges
7. Current Status of Potential Double Barreled Antibodies in Pipeline
7.1 BLINCYTO/Blinatumomab – Amgen Inc.
7.2 ABT-122 – AbbVie Inc.
7.3 MCLA-128 – Merus N.V.
7.4 ALX-0761/M1095 – Ablynx
7.5 MGD006/S80880 – MacroGenics, Inc.
7.6 ZW25 – Zymeworks Inc.
8. Trends and Developments
8.1 Bi-specific Antibody Application for Tumor Therapy
8.2 Bi-specific Antibodies Development Against Myeloma
8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
8.4 B-specific Antibody Development against Multiple Ebola viruses
9. Strategic Collaborations in the Double Barreled Antibody Industry
10. Competitive Assessment
10.1 Amgen Inc.
10.2 F. Hoffman La Roche Ltd.
10.3 AbbVie Inc.
10.4 OncoMed Pharmaceuticals, Inc.
10.5 Glenmark Pharmaceuticals Limited
10.6 Xencor, Inc.
10.7 MacroGenics, Inc.
10.8 Aptevo Therapeutics Inc.
10.9 Ligand Pharmaceuticals, Inc.
10.10 Regeneron Pharmaceuticals, Inc.
10.11 Fresenius SE & Co. KGaA
10.12 Merus N.V.

List of Figures:

Figure 3-1: Double Barreled Antibodies – Mechanism of Action
Figure 4-1: Global – Double Barreled Antibodies Market (Million US$), 2016-2022
Figure 4-2: Global – BLINCYTO Market (Million US$), 2015 & 2016
Figure 4-3: Global – Removab Market (Million US$), 2012 & 2013
Figure 5-1: Global – Double Barreled Antibodies Pipeline by Clinical Phase (%), 2016
Figure 5-2: Global – Double Barreled Antibodies Pipeline by Indication (%), 2016
Figure 5-3: Global – Double Barreled Antibodies Pipeline by Technology (%), 2016
Figure 6-1: Global – Cancer & Other Non-Communicable Disease Epidemics (%), 2016
Figure 10-1: Amgen Inc. – Breakup of Revenue by Geography (%), 2015
Figure 10-2: F. Hoffman La Roche Ltd. – Breakup of Group Sales by Business Segments (%), 2016
Figure 10-3: F. Hoffman La Roche Ltd. – Breakup of Group Sales by Geography (%), 2016
Figure 10-4: AbbVie Inc. – Breakup of Net Revenues by Geography (%), 2016
Figure 10-5: Glenmark Pharmaceuticals Limited, – Breakup of Revenue by Geography (%), FY 2016
Figure 10-6: Xencor, Incl. – Breakup of Revenue by Product Programs (%), 2016
Figure 10-7: Ligand Pharmaceuticals, Inc. – Breakup of Revenue by Operations (%), 2016
Figure 10-8: Ligand Pharmaceuticals, Inc. – Breakup of Royalty Revenue by Program (%), 2016
Figure 10-9: Ligand Pharmaceuticals, Inc. – Breakup of Material Sales by Use (%), 2016
Figure 10-10: Fresenius SE & Co. KGaA – Breakup of Sales by Business Segments (%), 2016
Figure 10-11: Fresenius SE & Co. KGaA – Breakup of Sales by Geography (%), 2016

List of Tables:

Table 4-1: Global – Potential Patients for BLINCYTO (2017)
Table 4-2: Global – Potential Patients for BLINCYTO (2020)
Table 4-3: Global – Ongoing Trials for BLINCYTO
Table 4-4: Global – Potential Patients for Removab, 2016
Table 4-5: Global – Potential Patients for Removab, 2020
Table 5-1: Global – Double Barreled Antibodies Pipeline
Table 9-1: Global – Strategic Collaborations in the Double Barreled Antibody Industry
Table 10-1: Top Companies by Double Barreled Antibodies in Pipeline, 2016
Table 10-2: Amgen Inc. – Product Portfolio
Table 10-3: Amgen Inc. – Double Barreled Antibodies in Pipeline
Table 10-4: Amgen Inc. – Key Financials (Million US$), 2013-2015
Table 10-5: F. Hoffman La Roche Ltd. – Double Barreled Antibodies in Pipeline
Table 10-6: F. Hoffman La Roche Ltd. – Key Financials (Million US$), 2014-2016
Table 10-7: AbbVie Inc. – Double Barreled Antibodies in Pipeline
Table 10-8: AbbVie Inc. – Key Financials (Million US$), 2014-2016
Table 10-9: OncoMed Pharmaceuticals, Inc. – Double Barreled Antibodies in Pipeline
Table 10-10: OncoMed Pharmaceuticals, Inc. – Key Financials (Million US$), 2014-2016
Table 10-11: Glenmark Pharmaceuticals Limited, – Double Barreled Antibodies in Pipeline
Table 10-12: Glenmark Pharmaceuticals Limited, – Key Financials (Million US$), FY 2014-2016
Table 10-13: Xencor, Inc. – Double Barreled Antibodies in Pipeline
Table 10-14: Xencor, Inc. – Key Financials (Million US$), 2014-2016
Table 10-15: MacroGenics, Inc. – Double Barreled Antibodies in Pipeline
Table 10-16: MacroGenics, Inc. – Key Financials (Million US$), 2014-2016
Table 10-17: Aptevo Therapeutics – Double Barreled Antibodies in Pipeline
Table 10-18: Ligand Pharmaceuticals, Inc. – Double Barreled Antibodies in Pipeline
Table 10-19: Ligand Pharmaceuticals, Inc. – Key Financials (Million US$), 2014-2016
Table 10-20: Regeneron Pharmaceuticals, Inc. – Double Barreled Antibodies in Pipeline
Table 10-21: Regeneron Pharmaceuticals, Inc. – Key Financials (Million US$), 2014-2016
Table 10-22: Fresenius SE & Co. KGaA – Product Portfolio
Table 10-23: Fresenius SE & Co. KGaA – Key Financials (Million US$), 2014-2016
Table 10-24: Merus N.V. – Double Barreled Antibodies in Pipeline



*** レポートのキーワード ***

二重抗体、医薬品

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"二重抗体医薬品の世界市場2022"は"RNCOS社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。